Grace Therapeutics CEO buys 100K shares at $2.14

Grace Therapeutics’ CEO and director increased his direct common stock holdings through a 100,000-share open-market purchase.

Rhea-AI Filing Summary

Grace Therapeutics, Inc. (GRCE) reported that Chief Executive Officer and director Prashant Kohli purchased 100,000 shares of common stock on September 9, 2026 in an open-market or private transaction at $2.14 per share. Following this purchase, he directly holds 121,357 shares of Grace Therapeutics common stock. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Buyer: 100,000 shares

Net Buy 1 txn

Insider Kohli Prashant

Role Chief Executive Officer

Bought 100,000 shs ($214K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	100,000	$2.14	$214K

Holdings After Transaction: Common Stock — 121,357 shares (Direct)

Key Figures

Shares purchased: 100,000 shares Purchase price: $2.14 per share Shares held after transaction: 121,357 shares

3 metrics

Shares purchased 100,000 shares Common stock acquired by CEO Prashant Kohli on September 9, 2026

Purchase price $2.14 per share Open-market or private purchase of Grace Therapeutics common stock

Shares held after transaction 121,357 shares Direct holdings of CEO Prashant Kohli following the reported purchase

Key Terms

Open market or private transaction, Rule 10b5-1, Common Stock

3 terms

Open market or private transaction financial

"Purchase in open market or private transaction"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for this transaction"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Common Stock financial

"purchased 100,000 shares of common stock on September 9, 2026"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GRCE report in this Form 4?

Grace Therapeutics reported that CEO and director Prashant Kohli purchased 100,000 shares of its common stock on September 9, 2026 in an open-market or private transaction at $2.14 per share.

How many GRCE shares does the CEO hold after this transaction?

After the reported purchase, CEO Prashant Kohli directly holds 121,357 shares of Grace Therapeutics common stock, as stated in the Form 4.

Was the GRCE CEO’s stock purchase made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed, so the reported 100,000-share purchase was not disclosed as being made under a Rule 10b5-1 trading plan.

What price did the GRCE CEO pay per share in this transaction?

The Form 4 reports that CEO Prashant Kohli purchased common stock at $2.14 per share on September 9, 2026 in an open-market or private transaction.

Is this GRCE Form 4 transaction a purchase or a sale?

This Form 4 reports a purchase transaction. CEO Prashant Kohli acquired 100,000 shares of Grace Therapeutics common stock and now directly holds 121,357 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 07:31 AM Accepted by SEC EDGAR 09/10/2026 - 07:30 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kohli Prashant

(Last) (First) (Middle)

C/O GRACE THERAPEUTICS, INC.

103 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Grace Therapeutics, Inc. [ GRCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2026		P		100,000	A	$2.14	121,357	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Robert DelAversano as attorney-in-fact for Prashant Kohli	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)